Oxford Nanopore Technologies PLC - Oxford, England-based company that develops and sells nanopore sequencing products - Enters a partnership with bioMerieux SA, a company in the field of in vitro diagnostics, to improve health outcomes. Says the partnership will explore opportunities to bring nanopore sequencing to the infectious disease diagnostics market.

Oxford Nanopore Chief Executive Officer Gordon Sanghera says: "We are pleased to partner with bioMerieux's IVD expertise to add powerful new tools for the fight against infectious disease. By offering rapid and accurate identification of pathogens and associated antimicrobial resistance, at scale, we hope to better equip the specialists for whom speed and access to comprehensive data is key."

Nanopore-based sequencing is a novel technology that enables analysis of long DNA or RNA fragments. Says both firms are jointly exploring selected opportunities to "advance patient care by providing access to nanopore-based clinical research and in vitro diagnostic solutions".

Current stock price: 239.80 pence each, up 1.2% on Monday morning in London

12-month change: down 30%

By Xindi Wei, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.